3.11 0.36 (13.09%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 4.02 | 1-year : | 4.7 |
Resists | First : | 3.45 | Second : | 4.02 |
Pivot price | 2.12 | |||
Supports | First : | 2.41 | Second : | 1.77 |
MAs | MA(5) : | 2.46 | MA(20) : | 2.08 |
MA(100) : | 2.45 | MA(250) : | 2.57 | |
MACD | MACD : | 0.1 | Signal : | 0 |
%K %D | K(14,3) : | 77.6 | D(3) : | 71.9 |
RSI | RSI(14): 79.9 | |||
52-week | High : | 4.62 | Low : | 1.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CHEK ] has closed above the upper band by 20.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 161.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 3.45 - 3.47 | 3.47 - 3.48 |
Low: | 2.48 - 2.5 | 2.5 - 2.51 |
Close: | 3.09 - 3.11 | 3.11 - 3.13 |
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
Thu, 28 Mar 2024
Check-Cap Ltd. Calls Shareholders to Vote on Executive Compensation and Board Changes - TipRanks.com - TipRanks
Thu, 28 Mar 2024
Check Cap Ltd (CHEK) Down 10.18% in Premarket Trading - InvestorsObserver
Thu, 28 Mar 2024
Check-Cap (CHEK) Scheduled to Post Quarterly Earnings on Friday - Defense World
Tue, 26 Mar 2024
AI-Powered Real Estate Marketplace Nobul AI To Acquire Medical-Diagnostics Company Check-Cap - MSN
Tue, 26 Mar 2024
Should You Buy Check Cap Ltd (CHEK) Stock Tuesday Morning? - InvestorsObserver
Tue, 26 Mar 2024
Check-Cap jumps on Nobul AI business combination (NASDAQ:CHEK) - Seeking Alpha
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Diagnostics & Research
|
|
Shares Out | 6 (M) |
Shares Float | 5 (M) |
Held by Insiders | 12.1 (%) |
Held by Institutions | 1.1 (%) |
Shares Short | 14 (K) |
Shares Short P.Month | 62 (K) |
EPS | -3.01 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 4.67 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -28.7 % |
Return on Equity (ttm) | -48.8 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -3.03 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -18 (M) |
Levered Free Cash Flow | -13 (M) |
PE Ratio | -1.04 |
PEG Ratio | 0 |
Price to Book value | 0.66 |
Price to Sales | 0 |
Price to Cash Flow | -1.04 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |